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Abstract
Folate deficiency has been associated with anemia 
and other adverse outcomes in pregnancy such as 
neural tube defects. The current recommenda-
tions for prevention of such outcomes are difficult 
to achieve through diet only, and folic acid sup-
plementation and food fortification are feasible 
public health strategies. However, it is necessary 
to determine the usual diet and supplement use 
among women of reproductive age, including an 
accurate assessment of other dietary micronutri-
ents. In addition to the beneficial effects observed 
in randomized clinical trials, health risks to the 
population have also been widely evaluated 
and discussed in the scientific community: for a 
minority to benefit from fortification programs, 
many are exposed to high folic acid intake levels.
Folic Acids; Pteroylpolyglutamic Acids; Nutrition-
al Epidemiology
Introduction
Data released by the World Health Organiza-
tion (WHO) show that women of reproductive 
age, along with infants younger than 2 years of 
age, are at their nutritionally most vulnerable 
stage in life 1. In contrast to trends in devel-
oped countries over the past 70 years, high rates 
of maternal morbidity and mortality persist in 
developing regions, particularly among low-in-
come women. Maternal mortality figures differ 
greatly between wealthy and poor nations, with 
the later accounting for 90% of such deaths 2. 
Around 160 million women become pregnant 
ever year, approximately 15% of whom develop 
serious preventable complications, and millions 
of newborns do not survive the first week of life 
due to the absence or lack of proper prenatal 
healthcare 3.
One of the indirect complications contrib-
uting to maternal health (and consequently to 
infant health) is maternal anemia. Anemia is es-
pecially common among women of reproduc-
tive age secondary to menstrual bleeding and to 
physiological changes during pregnancy 4, yet 
remains prevalent owing to limited availability of 
diagnostic and treatment services.
From a nutritional standpoint, deficiencies 
in iron, vitamins B12, A and folate cause hema-
tologic changes which if untreated can evolve to 
an anemic state 5. Folic acid has been a focus of 
research for the past 30 years given its role in the 
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prevention of another condition: neural tube clo-
sure defects. 
The role of folic acid in biochemical reac-
tions, such as those involved in metabolism of 
aminoacids and in the synthesis of DNA, ren-
ders it a critical nutrient in embryogenesis. Dur-
ing embryogenesis closure of the neural tube, 
the structure from which the brain and spinal 
column are derived, takes place 6. Neural tube 
closure defects can lead to death of the infant 
or to serious life-long complications. There is 
evidence for a protective effect against these 
defects through pre and periconceptional folate 
supplementation 7.
Folic acid supplementation in women was 
therefore introduced to address two principal 
problems: maternal anemia and neural tube 
closure defects. In view of limited adherence to 
supplementation however, food fortification was 
subsequently proposed for prevention of neural 
tube closure defects. The aim of the present study 
was to consider both these outcomes by analyz-
ing and summarizing the recommendations and 
conducts pertaining to consumption of this vita-
min in light of the latest scientific evidence.
Definitions and background
Although the umbrella term “folic acid” has 
been adopted in this article to denote all forms 
of the vitamin, including those found in plasma 
and erythrocytes, there are key differences be-
tween folate (occurring naturally in foods) and 
oxidized folic acid (synthetic form used in sup-
plements and fortified foods). Folate is in the 
form of polyglutamates (pteroylpolyglutamate) 
whereas folic acid is in monoglutamate (pte-
roylmonoglutamate) form. Polyglutamates have 
higher metabolic activity and are better retained 
by cells, while monoglutamates pass through cell 
walls more rapidly. In humans, the metabolism 
of polyglutamates requires their deconjugation 
to monoglutamates within enterocytes, explain-
ing their low bioavailability (~50%) compared to 
monoglutamates (~85%) 8. Moreover, anti-folate 
components present in vegetables as well as ex-
posure to heat and light during cooking and stor-
age, all contribute to lowering folate availability 9.
Differences in bioavailability hamper the es-
tablishing of recommendations. To adjust for the 
bioavailability differences between folate and 
folic acid, Dietary Folate Equivalents (DFE) are 
used. The DFE assumes that the bioavailability of 
folic acid added to foods is 1.7-fold greater than 
that of natural folate (mathematically, DFE = fo-
late + 1.7 x folic acid) 10. An individual’s folate acid 
status therefore depends on the source of the vi-
tamin in the diet as well as the absolute amount 
consumed.
Folic acid supplementation was primarily 
indicated for the prevention and treatment of 
megaloblastic and maternal anemia 11. Supple-
mentation is also indicated in individuals with a 
genetic defect requiring greater amounts of folate 
than can be derived from the diet 12. Based on 
evidence that folic acid also prevents neural tube 
closure defects 13, supplementation in public 
health programs was recommended, particularly 
since, unlike megaloblastic anemia, sera concen-
trations of folic acid in mothers of children with 
neural tube defects were normal 14. Against this 
background, the present article discusses the 
importance of recommendations of folic acid 
in public health programmes for the prevention 
and control of two different outcomes, namely: 
anemia during pregnancy and neural tube clo-
sure defects.
Anemia during pregnancy
Around one million maternal and infant lives are 
cut short every year due to anemia, a condition 
associated to low birth weight, prematurity and 
neonatal mortality, and a cause of disablement, 
mental retardation and compromised work per-
formance 15.
Anemia has multiple causes including blood 
loss, parasitic infections, cancer, hemoglobin-
opathies, malaria and deficiencies in nutrients 
such as iron, vitamins B12, A, riboflavin and fo-
lic acid 15. The contributions of nutritional fac-
tors to the etiology of anemia can vary according 
to age, physiological state and socio-economic 
conditions, such that interpretation of a specific 
marker in isolation is not valid in scenarios where 
the etiology of anemia may be more complex. 
The WHO considers anemia a global public-
health problem: a significant proportion of wom-
en of reproductive age (29.6%) live in countries 
where anemia is a serious health problem (ane-
mia prevalence ≥ 40%), and over half the global 
population of pre-school children (56.3%) and 
pregnant women (57.5%) reside in such coun-
tries, the majority of which are located in Af-
rica, Asia and Latin America 16. Studies on the 
prevalence of folic acid deficiency and also on 
the hematological response to folic acid in Brazil 
are scarce 17. According to Metz 18, anemia due 
to folic acid deficiency in developed countries 
is rare, but still occurs in developing countries, 
especially in areas endemic for malaria and with 
a high incidence of iron deficiency anemia, he-
moglobinopathies and HIV. 
Population-based data for Brazil reveals that 
the occurrence of anemia among women of re-
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productive age (10-49 years) ranges from 15.2% 
(rural zone of Pernambuco) to 26.2% (Piaui), 
and from 14.7% (Rio de Janeiro) to 40.4% (Recife, 
Pernambuco) among pregnant women 19. In São 
Leopoldo, Rio Grande do Sul, a transversal study 
on a representative sample of 312 women (20-60 
years) found an overall prevalence of 19.2%, and 
double this rate among negro women (54%) 20. 
There is a lack of representative data for other 
regions in Brazil for the past ten years estimat-
ing the magnitude of the problem in women of 
reproductive age.
The Department of Nutrition for Health 
and Development of the WHO summarized 
the current recommendations for creating and 
implementing public health intervention pro-
grammes 21. Weekly iron-folic acid supplemen-
tation, in synchrony with enterocyte turnover, 
was proposed as an equally effective preventive 
measure as daily supplementation in public-
health programmes, and a more optimal ap-
proach given its lower side-effects and ease of 
administration in community settings 22. It is 
important that an assessment is carried our 
prior to commencing interventions and once 
running, programmes should be monitored on a 
monthly basis to check processes and outcomes 
throughout the first year, and then verified every 
five years thereafter.
In Brazil, the goal of the National Programme 
of Supplementation with Iron, proposed by the 
General Coordination of Food and Nutrition 
Policy (CGPAN), is to reduce the prevalence of 
anemia in infants aged 6-18 months, in pregnant 
women and women after child birth or miscar-
riage 23. This is the first Brazilian programme of 
its kind to consider both supplementation with 
iron and provision of folic acid to target groups: 
5mg/day of the vitamin administered from the 
20th week of pregnancy up until childbirth. Ac-
cording to the guidelines of the Institute of Medi-
cine, the recommended dose to prevent anemia 
in pregnant women is 0.4mg/day of folic acid 
(diet + supplement) 24, with a maximum safe 
dose of 1mg/day 10. Given the known and un-
known adverse effects of over-supplementation 
with this vitamin, further studies reassessing this 
programme are needed.
Table 1 contains the recommendations for 
iron and folic acid supplementation in women 
for anemia prevention.
Neural tube closure defects
The neural tube normally closes within four 
weeks of conception or two weeks after interrup-
tion of menstruation. Cases of neural tube clo-
sure defect can lead to the pregnancies ending 
in miscarriage, stillbirth or in a child who may 
experience life-long medical complications 25. 
Genetic, nutritional and environmental factors, 
or a combination of these, play a definitive role in 
the development of these conditions. 
• Genetics
Blom et al. 26 proposed the theory of methylation, 
according to which problems in the methylation 
of lipids, DNA and protein during embryogenesis 
translate to a higher risk for neural tube defects 
in individuals with specific mutations. The en-
zyme 5,10-methylenetetrahydrofolate reductase 
(MTHFR) catalyzes the irreversible reduction of 
5,10-methylenetetrahydrofolate to 5-methyle-
netetrahydrofolate, a methyl donor for biosyn-
thesis of methionine and nucleotides. Mutations 
in MTHFR have been associated to greater risk 
of neural tube defects in some populations 27 yet 
not in others 28. Other genes may influence the 
methylation cycle either through remethylation 
(MTR, MTRR, BHMT and BHMT2) or by trans-
sulfuration (CBS) of homocysteine, compromis-
ing methylation and increasing homocysteine 
concentrations which are in turn associated to 
greater risk of neural tube defects 29. A second 
hypothesis centers on the genes codifying to en-
zymes needed for nucleotide biosynthesis: there 
is evidence that a polymorphism in methyl-
enetetrahydrofolate dehydrogenase (MTHFD1) 
is associated with a higher risk of neural tube de-
fects in Italian 30, but not English 31, populations. 
The third theory concerns the genes codifying 
proteins involved in the transport, capture and 
cell retention of folate, such as the reduced fo-
late carrier (RFC), folyl-gamma-glutamate car-
boxypeptidase (GCP2) and folylpolyglutamate 
synthase (FPGS), although not all studies have 
confirmed neural tube defect risk 32. 
• Nutrition
After the identification of folic acid as an impor-
tant vitamin in the occurrence/reoccurrence of 
neural tube defects 33, numerous studies ensued 
assessing associations between diet and neural 
tube defects. Folic acid acts as a donor of methyl 
groups in the synthesis of DNA, and the relation-
ship between folic acid deficiency and neural 
tube defects may be linked to lower gene expres-
sion, given that methylation of DNA influences 
transcription and genomic stability 34. Gene-
nutrient interaction has been observed in recent 
studies: the effect of the mutant homozygosis 
of the MTHFR C677T polymorphism on homo-
cysteine concentrations, a risk factor for neural 
tube defect, was reduced by moderate daily in-
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take of folic acid 35. It is noteworthy that neural 
tube defects constitute only one of the many 
problems linked to folic acid deficiency, since the 
vitamin is implicated in the etiology of other con-
genital anomalies such as Down’s syndrome 36, 
cleft lip and palate defects 37.
• Environment
A low level of maternal education 38 and food 
shortage 39 have been identified as possible risk 
factors for neural tube defects, in addition to 
the use of medications which interfere with the 
metabolism of folic acid (anti-epileptics, aspirin, 
methotrexate, sulfasalazine etc.), hyperthermia, 
use of tobacco and excessive doses of vitamin A 
(> 15,000IU) during pregnancy 40. The presence 
of abdominal obesity, diabetes mellitus and dys-
lipidemia may increase risk six-fold 41, while obe-
sity alone almost doubles the risk of neural tube 
defects 42.
Technical advances in ultra-sonography pro-
viding more enhanced resolutions, together with 
the interruption of affected pregnancies, food for-
tification and intake of supplements containing 
folic acid, have substantially reduced the global 
Table 1
Recommendations for iron and folic acid supplementation in women for prevention of anemia.
Target population Nutrient Product Dose Frequency Start Duration Source
Women of reproductive 
age *
Iron Iron sulfate 60mg 1x/week 3 months prior 
to conception
3 months WHO 21
Folic acid ** Pteroylmono-
glutamate acid
180µg *** 1x/day IoM 24
Pregnant women Iron Iron sulfate 60mg # 1x/day 20th week of 
pregnancy
Up to 3 months 
post-partum
WHO 21
Folic acid Pteroylmono-
glutamate acid
0.4mg *** 1st month of 
pregnancy ##
Until end of 
pregnancy
IoM 24
Women after birth or 
miscarriage
Iron Iron sulfate 60mg 1x/day Immediately 
after birth
3 months WHO 21
Folic acid Pteroylmono-
glutamate acid
0.4mg ***
IoM: Institute of Medicine; WHO: World Health Organization.
* In population groups where the prevalence of anemia is greater than 20% among women of reproductive age, weekly supplementation should be considered 
as a strategy for preventing iron defi ciency, improving pre-pregnancy iron reserves and improving folate status in some women. In the absence of anemia data 
for this group, the prevalence of anemia (> 40%) in other groups can be used as proxy: pregnant women or children aged < 5 years. In the absence of this 
data, criteria such as dietary and socio-economic patterns may be employed 21;
** Supplementation with folic acid in this group may not be required in two situations: within regions where food fortifi cation has proven effective; and in 
regions endemic for malaria where anti-folate treatment is employed, since evidence suggests that supplementation with folic acid may reduce the effi cacy of 
these drugs 21;
*** Diet + supplement;
# Studies show that low daily doses of iron (30mg) during pregnancy improves maternal iron status and appears suffi cient to protect the child from 
iron-defi ciency anemia 10;
## No collateral effects have been reported as a result of supplementation with folic acid from start of pregnancy.
prevalence of neural tube defects over the last 
three decades. These defects have an incidence 
of 1-2/1,000 births, varying with race and geo-
graphic region 40 both within and between coun-
tries. Worldwide, an estimated 240,000 cases of 
spina bifida and anencephaly, the most common 
forms of neural tube defects, occur annually 43.
The role of folic acid deficiency in pregnancy 
complications, such as higher rates of miscar-
riage and fetal malformation, was first studied 
in the 1960s 44, but the vitamin’s role in prevent-
ing neural tube defects was only identified in the 
1980s and 1990s 13. Since this discovery, the con-
sumption of folic acid-fortified foods and supple-
ments have been recommended periconceptu-
ally in all American women of child-bearing age 
(0.4mg/day to prevent a first occurrence of neural 
tube defect; 4mg/day to prevent a recurrence), in 
addition to a healthy diet 45. A recent systematic 
review indicated that periconceptional supple-
mentation with folic acid alone had a protective 
effect of 72% against neural tube defects, but may 
influence multiple births 7.
In developing countries, the majority of preg-
nancies are unplanned 46, and this has been cited 
as the main stumbling block in implementing 
FOLATE INTAKE IN WOMEN 2015
Cad. Saúde Pública, Rio de Janeiro, 26(11):2011-2026, nov, 2010
recommendations to take folic acid for the pre-
vention of neural tube defects. The disappoint-
ing results of public-health campaigns aimed at 
increasing the use of supplements 47 led to man-
datory fortification of foods as an optimal solu-
tion to reach women in early stages of pregnancy. 
Over 50 countries, including Brazil, now fortify 
foods using folic acid 48, sparking worldwide de-
bate on its benefits and risks.
In Brazil, congenital defects have a significant 
impact on infant morbidity and mortality, and 
constitute the second most frequent cause of in-
fant death (13%) in the first year of life 49. The cit-
ed study highlights the governmental and non-
governmental actions in the country, evidencing 
the urgent need for a specific policy aimed at the 
support, treatment and prevention of congenital 
defects which, in the current context, hinge more 
on good planning than on technology.
The recommendations for folic acid supple-
mentation in women for the prevention of neural 
tube defects are summarized in Table 2.
Use of synthetic folic acid
Supplementation
Ray et al. 50 reviewed the prevalence of folic acid 
supplementation in community programmes 
worldwide and found a variation of 0.9% (South-
ern Israel) to 49% (Vancouver, Canada) during 
the preconception period and 0.5% (Sicily, Italy) 
to 52% (Holland) during the periconceptional 
period. In the United Kingdom, the leading 
factor underlying low adherence was uninten-
tional pregnancies, followed by the young age of 
mothers, low income and Hispanic ethnicity 51. 
In Korea, a prevalence of periconceptional folic 
acid supplement use of 10.3% was observed, and 
was associated to a history of spontaneous mis-
carriage, planned pregnancy and knowledge of 
the benefits of folic acid 52. Although the use of 
dietary supplements by pregnant and nursing 
American women has been little studied, data 
from the 1999-2000 National Health Nutrition 
Survey (NHANES) 53 showed that 52% of Ameri-
can adults took dietary supplements.
Knowledge on prevalence of folic acid sup-
plement use during pregnancy in Brazil is scarce. 
A population-based transversal study (Pelotas, 
Rio Grande do Sul) reported a prevalence of folic 
acid supplement use during pregnancy of 31.8% 
versus 4.3% in the periconceptional period 54.
Many studies are available investigating the 
positive link between folic acid supplement use 
and improved nutritional status of the vitamin 
among women 55. A random uncontrolled clini-
cal trial (n = 40) was conducted comparing eryth-
rocyte folic acid concentrations in women who 
were not pregnant (18-45 years) after supple-
mentation with 1.1mg or 5mg/day of folic acid 
for 30 weeks. The results concluded that the 5mg 
group had significantly higher erythrocyte folate 
Table 2
Recommendations for folic acid supplementation in women for prevention of neural tube defects.
Target population Nutrient Product Dose * Frequency Start Duration Source
Women of reproductive 
age **
Folic acid Pteroylmono-
glutamate 
acid
0.4mg 
(if no previous 
pregnancy 
affected by neural 
tube defect);or
1x/day 3 months 
prior to 
conception
6 months WHO 21
2.8mg 1x/week ***
4.0mg 
(if a previous 
pregnancy was 
affected by neural 
tube defect)
1x/day
WHO: World Health Organization.
* Supplement, in addition to that provided by the diet;
** Because closure of the neural tube takes place by the 28th post-conception day, supplementation to prevent neural tube defects will only have an effect if 
started during the periconceptional period; however, this dose is still recommended by WHO specialists even after onset of pregnancy 3; 
*** Weekly supplementation is an option only for women of reproductive age; after becoming pregnant, the WHO recommends daily supplementation as 
listed above 21.
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concentrations than the 1.1mg group at study 
endpoint 56. The authors adopted a cut-off point 
of 906nmol/L of erythrocyte folate as protec-
tive against neural tube defects, although failed 
to point out that the group supplemented with 
1.1mg attained steady state erythrocyte folate 
concentrations (1,625 ± 339nmol/L) at levels 80% 
greater than the cut-off point. The cited study 
was funded by a pharmaceutical company.
Users of the supplement tend to take higher-
than-recommended doses. A pharmacoepide-
miological study in pregnant users of pre-natal 
primary care services in the city of Piracicaba, 
São Paulo, found that 47.9% of prescriptions were 
above the recommended daily dose 57.
Fortification
According to estimates by Bell & Oakley Jr. 58, 27% 
of the world population has access to flour forti-
fied with iron and/or folic acid. Fortification with 
folic acid produced positive results in the United 
States 59, Canada 60 and Chile 61, reducing the fre-
quency of neural tube defects. Other possible im-
pacts of this policy are emerging, some potential-
ly beneficial such as lower plasma homocysteine 
levels 62, and some harmful. Investigations car-
ried out in the last decade have suggested that 
excessive intake of synthetic folic acid may pro-
mote the progression of undiagnosed neoplas-
tic lesions, as seen with aberrant methylation 
of DNA in colorectal carcinogenesis 63, and has 
been linked to recurrent early pregnancy loss 64, 
vitamin B12 deficiency 65 and multiple births 66.
The Medical Research Council Vitamin Study 
(MRC), a random double-blind controlled clini-
cal trial was a reference study for the establish-
ment of the recommendation of 0.4mg/day of 
folic acid in women of reproductive age, lead-
ing to an estimated decrease in the incidence of 
neural tube defects of around 70% 13. It is im-
portant to note however that the MRC sample 
comprised women who had previous pregnan-
cies affected by neural tube defects and also that 
the placebo group was not “pure” (having taken 
iron and calcium pills). A study 67 assessing the 
relationship between folic acid supplementation 
and its sera levels (involving clinical trials which 
used folic acid doses > 1mg/day) and the effect 
of folic acid levels on the occurrence of neural 
tube defects (based on results from a cohort of 
56,000 pregnant women) found that for a 0.4mg/
day increase in folic acid intake, the reduction in 
risk for neural tube defects depended on the ini-
tial sera concentration of the vitamin, where the 
higher the initial concentrations, the lower the 
preventive effect. Moreover, for a given increase 
in folic acid intake, the sera concentrations of 
the vitamin increased more in older individuals 
than in younger ones 67. Thus, it is questionable 
whether the recommended 0.4mg/day of folic 
acid for preventing neural tube defect applies to 
all population groups. 
With regard to fortification, the quantity of 
folic acid (140µg/100g of flour) was determined 
with the intention of providing an additional av-
erage intake of 100µg/day, while preventing daily 
intake from exceeding 1 mg/day in American 
adults. Nevertheless, later studies showed that 
fortification in the United States was supplying 
more than twice the mandated amount 68. Some 
months after fortification, reductions in folic acid 
deficiency were observed along with lower rates 
of hyperhomocysteinemia in the American gen-
eral population, as well as a fall in the incidence 
of neural tube defects69. In parallel, the frequency 
of high blood folate concentrations (> 20ng/L) 
also rose among children and the elderly from 5% 
and 7% to 42% and 38%, respectively 70. After a 
period of overexposure to folic acid however, the 
intake of the vitamin was found to dip in Ameri-
can women of reproductive age, supposedly due 
to the popularity of low carbohydrate diets with 
consequent reduced levels of fortification. This 
phenomenon may explain the decrease in sera 
and erythrocyte folate concentrations seen in the 
NHANES survey from 1999-2004 71, suggesting 
that the effect of fortification on the risk of neural 
tube defects may be lower first assumed.
Studies on data from the Framingham Off-
spring Cohort showed that fortification more than 
doubled serum folate and increased erythrocyte 
folate by 30%, and led to a 50% reduction in the 
prevalence of high homocysteine. In Australia, 
a population-based study found a 38% increase 
in serum folate and a 21% decrease in average 
homocysteine concentration 72.
Fortification in Canada has led to an estimat-
ed reduction in prevalence of open neural tube 
defects of 50% 73 to 70% 74. Molloy et al. 75 argued 
that increased levels of fortification in these areas 
are unlikely to further reduce the prevalence of 
neural tube defects, and it is therefore necessary 
to identify other modifiable risk factors such as 
inadequate vitamin B12 status.
The Brazilian government introduced man-
datory fortification of wheat and maize flour 
with 150µg/100g in June 2004 76. The National 
Institute of Metrology, Normalization and Indus-
trial Quality (INMETRO) analyzed six brands of 
corn flour (3 sourced from Paraná state, 2 from 
Rio de Janeiro and 1 from Minas Gerais) and all 
conformed to the minimum quantity required 
by law 77. Soeiro et al. 78 assessed folic acid in 
samples of five brands of wheat flour and three 
brands of corn flour in the city of Campinas, São 
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Paulo: 12% (wheat) and 21% (corn) of the sam-
ples tested contained the quantity recommend-
ed by law, 60% (wheat) and 21% (corn) were low 
in folic acid, while 28% (wheat) and 58% (corn) 
exceeded mandated levels. Although these find-
ings are important, there is currently a lack and 
need of national data quantifying folic acid in 
these flours and their derivatives.
To date, no population-based studies have 
been conducted assessing the impact of flour 
fortification with folic acid on the prevalence 
of neural tube defects in Brazil. A longitudinal 
study using data from the National System of Live 
Births (SINASC) from 2000 to 2006 (n = 161,341) 
carried out in Recife found no statistically sig-
nificant difference between prevalence of neural 
tube defects during pre-fortification (0.75:1,000 
live births) and post-fortification (0.51:1,000 live 
births) periods 79. Preliminary data are available 
for other South American countries from the 
Latin-American Collaboration Study on Con-
genital Malformations (ECLAMC) for the period 
spanning from 1999 to 2001 80. Among countries 
included in the survey, only Chile, where fortifi-
cation levels have been 220µg/100g of flour since 
2000, showed a statistically significant reduction 
in rates of neural tube defects, although the au-
thors did not rule out the possibility of “ecologi-
cal fallacy”.
The process of implementing fortification 
programmes in some countries, particularly in 
Europe, has been guided by comprehensive ap-
praisal plans for monitoring the effectiveness 
and safety of the interventions. In Ireland for ex-
ample, after accepting the recommendation of 
the National Committee on Folic Acid Food Forti-
fication in 2006, the government charged a group 
of specialists to perform a preparatory study prior 
to implementing the programme for mandatory 
fortification of bread. Key indicators for assess-
ing the future effects of higher folic acid intake 
by the population were studied: prevalence and 
incidence of pregnancies affected by neural tube 
defects; estimate of the degree of voluntary for-
tification with folic acid; blood folic acid status 
among subgroups of the population 81. 
According to a guidelines published by the 
WHO 82, implementation of a food fortifica-
tion programme entails the following steps: (1) 
determination of the nutritional status of the 
population with regard to the nutrient in ques-
tion; (2) election of a suitable food vehicle; (3) 
establishment of the acceptability and stability 
of the fortified vehicle; (4) assessment of the bio-
availability of the nutrient in the chosen vehicle; 
(5) conducting of a controlled field study and; (6) 
implementation of a regional or national fortifi-
cation programme.
In Brazil’s case, with regard to adherence to 
the steps outlined above, there have been insuf-
ficient studies assessing whether all age groups, 
or regions of the country have benefited from for-
tification (step 1). Table 3 contains a calculation 
of folic acid consumption based on estimates 
of food expenditure drawn from the Brazilian 
Household Budget Survey (HBS) 83, based on the 
assumption that fortification in Brazil takes place 
as stipulated by law (150µg/100g flour). Values 
approach those expected for the United States, of 
around 100µg/day from fortification, yet it is per-
tinent to ask: What is the distribution of the folic 
acid deficiency across different regions of Brazil?
Which age/physiological groups benefit from 
fortification? Do these groups consume wheat or 
corn flour? Is any specific group at risk ?
In fact, the lack of nationally representative 
data on folic acid status is a problem common 
to other countries worldwide. A recent review17 
revealed that only ten countries (Costa Rica, 
France, Germany, Mexico, New Zealand, Nor-
way, Switzerland, England, the United States and 
Venezuela) conduct surveys on folic acid status 
among the national population, although data 
generally relates to specific age or physiological 
groups thereby precluding extrapolation. 
The decision to elect wheat and corn flour 
as the vehicles for folic acid in Brazil (step 2) 
was based on the premise that these foods are 
widely consumed by the Brazilian population. 
These flours however, constitute ingredients 
of processed foods such as cakes and biscuits 
(creams or otherwise) which are sources of nu-
trients known to be harmful to health, including 
simple carbohydrates and saturated and trans 
fats. Manufacturers of these products exploit the 
fortification factor as a selling point in their mar-
keting strategy. 
With regard to step 3, international studies 
have demonstrated that folic acid in flour was or-
ganoleptically well accepted, given that its stabil-
ity was not significantly changed 84. It was found 
that the addition of folic acid, as well as other 
nutrients, at different levels of fortification, had 
only a marginal effect 85.
In terms of the bioavailability of folic acid in 
vehicles chosen (step 4), amounts up to 0.5mg/
kg of wheat or corn flour yielded bioavailability 
of over 85% 86.
Community surveys (step 5) should be con-
ducted in order to assess potential risks and ef-
ficacy of fortification across different regions in 
Brazil. Despite the absence of these studies, the 
fortification programme went ahead in Brazil.
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Table 3
Average folic acid (FA) intake in Brazil based on estimated food expenditure from the 2002-2003 Brazilian Household Budget Survey (HBS) 83.
Food item FA or folate 
content 
(ug)/100g 
flour or 
natural source
All regions North Northeast
Daily dietary 
intake per 
capita (g)
Estimated 
FA or folate 
intake (µg)/
day
Daily dietary 
intake per 
capita (g)
Estimated 
FA or folate 
intake (µg)/
day
Daily dietary 
intake per 
capita (g)
Estimated 
FA or folate 
intake (µg)/
day
Fortified foods 128.07 85.27 128.19
Wheat flour 150 13.93 20.90 5.91 8.87 4.07 6.11
Corn cream sauce 150 0.50 0.75 0.17 0.25 1.55 2.33
Corn flakes 150 1.03 1.55 0.37 0.55 2.12 3.18
Corn flour 150 8.73 13.10 4.69 7.04 16.45 24.68
Pastry * (70% wheat flour) 150 9.17 13.76 5.98 8.97 9.02 13.53
Bread * (80% wheat flour) 150 44.49 66.74 34.56 51.84 43.44 65.16
Cakes * (50% wheat flour) 150 0.95 1.43 0.31 0.47 0.62 0.92
Biscuits * (50% wheat flour) 150 6.58 9.87 4.85 7.27 8.18 12.27
Natural sources 10.18 7.45 14.34
Boiled spinach 146 0.43 0.63 0.07 0.11 0.61 0.88
Cow’s liver 253 1.17 2.96 1.49 3.76 1.54 3.90
Cooked beans 48 4.32 2.07 2.13 1.02 14.64 7.03
Raw beetroot 109 1.15 1.25 0.82 0.89 0.68 0.74
Boiled broccoli 108 0.30 0.32 0.02 0.02 0.01 0.01
Iceberg lettuce 29 1.76 0.51 1.72 0.50 1.15 0.33
Boiled cauliflower 44 0.48 0.21 0.07 0.03 0.07 0.03
Oranges 30 6.01 1.80 1.93 0.58 4.22 1.26
Boiled kale 93 0.35 0.33 0.50 0.47 0.10 0.09
Cucumber with skin 7 1.33 0.09 1.03 0.07 0.89 0.06
Fortified foods + natural 
sources
138.25 92.72 142.52
(continues)
Food item Southeast South Mid-west
Daily dietary 
intake per capita 
(g)
Estimated FA 
or folate intake  
(µg)/day
Daily dietary 
intake per capita 
(g)
Estimated FA 
or folate intake  
(µg)/day
Daily dietary 
intake per capita 
(g)
Estimated FA 
or folate intake 
(µg)/day
Fortified foods 123.89 184.50 81.76
Wheat flour 10.17 15.25 49.25 73.87 10.72 16.08
Corn cream sauce 0.12 0.17 0.02 0.02 0.04 0.05
Corn flakes 0.85 1.28 0.18 0.27 0.23 0.35
Corn flour 5.87 8.81 7.47 11.20 2.45 3.68
Pastry * (70% wheat flour) 9.67 14.51 10.83 16.25 6.75 10.12
Bread * (80% wheat flour) 48.65 72.98 46.72 70.08 29.54 44.31
Cakes * (50% wheat flour) 1.12 1.67 1.68 2.52 0.52 0.78
Biscuits * (50% wheat flour) 6.14 9.21 6.85 10.28 4.25 6.38
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Table 3 (continued)
Adverse effects of synthetic folic acid 
The debate over fortification with folic acid, de-
spite its success in reducing rates of neural tube 
defects in some countries, has intensified in re-
cent years in light of several fresh theories and 
findings 87,88.
A study on immune function in post-meno-
pausal women found that activity of natural 
killer cells was influenced by intake of folic acid 
supplements ≥ 400µg/day. Natural killer activity 
is important in the defense against infection as 
well as in eliminating cancerous cells. This ac-
tivity was reduced by 25% in women who con-
sumed diets with adequate folate supplemented 
with folic acid. Moreover, unmetabolized folic 
acid was detected in the blood of 78% of women 
in this group 89.
Kelly et al. 90, in an uncontrolled, random 
clinical trial, found levels of unmetabolized se-
rum folic acid post-prandially in volunteers (18-
42 years) who consumed bread fortified with 
266µg of folic acid/meal for five days. These au-
thors pointed out that, depending on the levels 
of fortification, unmetabolized folic acid can 
persist in plasma for many years, particularly in 
individuals consuming large amounts of forti-
fied foods. The authors also called for a review of 
the 1mg/day Tolerable Upper Level Intake (UL) 
of folic acid. Many women who adhere to the 
400µg/day recommendation may present con-
sistently high concentrations of unmetabolized 
folic acid in plasma. The saturation of dihydrofo-
late reductase (DHFR), an enzyme which slowly 
converts folic acid into tetrahydrofolate for use 
by the organism, partially explains the build-up 
of unmetabolized folic acid in plasma, implying 
that benefits of consuming high doses of folic 
acid are indeed limited 91.
Several mechanisms have been postulated 
as contributing to the risk of disease among in-
dividuals taking folic acid supplements and fre-
quently manifesting unmetabolized folic acid in 
the bloodstream. One such effect is based on the 
fact that folic acid shares the same mechanisms 
of cell transport as MTHF in most tissues, mean-
ing that high blood folic acid levels may compete 
for cellular transport with MTHF, needed for 
normal metabolic reactions. Studies have shown 
that gene expression of the cellular transporters 
decreases after incubation of human intestinal 
and renal cells with high concentrations of fo-
lic acid 92. Another proposed mechanism is that 
high intracellular concentrations of folic acid may 
promote the synthesis and use of greater quanti-
ties of MTHF which, through its B12-dependent 
pathway for DNA synthesis, may deplete vitamin 
B12 needed for normal cognitive function 93.
A number of studies have shown a relation-
ship between use of folic acid supplementation 
and higher risk of cancer. A prospective, nine-
year study involving more than 11,000 individu-
als in Sweden, a country without mandatory 
fortification, showed a lower incidence of breast 
cancer in women with high folic acid intake 94. 
Another study in a cohort of over 25,000 post-
Natural sources 8.97 8.60 7.21
Boiled spinach 0.35 0.50 0.64 0.93 0.14 0.20
Cow’s liver 1.15 2.92 0.45 1.14 1.00 2.54
Cooked beans 0.10 0.05 0.08 0.04 0.15 0.07
Raw beetroot 1.21 1.32 1.63 1.78 1.95 2.13
Boiled broccoli 0.54 0.58 0.42 0.45 0.04 0.04
Iceberg lettuce 1.84 0.53 2.76 0.80 1.67 0.49
Boiled cauliflower 0.78 0.34 0.68 0.30 0.29 0.13
Oranges 7.98 2.39 6.82 2.04 4.02 1.21
Boiled kale 0.26 0.24 1.02 0.95 0.32 0.30
Cucumber with skin 1.27 0.09 2.37 0.17 1.50 0.10
Fortified foods + natural 
sources
132.86 193.10 88.97
* Values in parentheses represent estimated average percentage of wheat or corn fl our contained in the food.
Food item Southeast South Mid-west
Daily dietary 
intake per capita 
(g)
Estimated FA 
or folate intake  
(µg)/day
Daily dietary 
intake per capita 
(g)
Estimated FA 
or folate intake  
(µg)/day
Daily dietary 
intake per capita 
(g)
Estimated FA 
or folate intake 
(µg)/day
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highest quintile of folic acid intake, derived 
from both diet and supplements 95. A prospec-
tive study in more than 1,000 men and women 
followed up for ten years after surgical resection 
for colorectal cancer found a 52% greater risk of 
recurrence of high-grade dysplastic adenomas in 
individuals taking folic acid supplements (10.9%) 
compared with those taking placebo (4.3%) 96. 
Knowledge on the mechanisms by which folic 
acid stimulates the development of some types 
of cancer is explored in the process of devising 
anti-cancer drugs, which interfere in the func-
tioning of enzymes metabolizing the vitamin 97.
Genetic damage in the presence of synthetic 
folic acid have also been a focus of investiga-
tions. A controlled, double-blind, random clini-
cal trial in 56 healthy male and female volunteers 
(20-60 years) observed a significant decrease in 
the incorporation of uracil (p < 0.05) in a sup-
plemented group (1.2 mg folic acid) compared 
to a placebo group (glucose). Incorporation of 
uracil was more sensitive to folic acid status in 
healthy volunteers than other biomarkers of DNA 
damage 98.
Through their metabolic interactions, fo-
lic acid and vitamin B12 protect the organism 
against anemia and cognitive decline. Vitamin 
B12 is needed for the functioning of methionine 
synthase, the enzyme responsible for remethy-
lation of homocysteine to methionine and for 
converting N5-methylTHF to THF. In conditions 
of B12 deficiency, folic acid remains in N5-meth-
ylTHF form and N5, N10-methyleneTHF needed 
for DNA synthesis is not produced leading to 
erythrocyte macrocytosis. If the diet is supple-
mented with high doses of folic acid, macrocy-
tosis secondary to vitamin B12 deficiency can be 
corrected since excess folic acid is converted into 
dihydrofolate (DHF) which is then converted in-
to THF, restoring the process of normal DNA syn-
thesis 99. A study involving more than 1,500 el-
derly from the 1999-2002 NHANES survey found 
that low vitamin B12 status with normal folic 
acid status (20% of group) doubled anemia risk 
to 7%, while increasing dementia risk from 18% 
to 25%. In addition, the incidences of anemia 
and dementia in individuals with low B12 status 
yet high folic acid status due to supplements use 
(3.3 % of group), increased significantly to 15% 
and 45%, respectively100. 
These studies are summarized in Table 4.
Final considerations
The inclusion of family planning campaigns into 
the routine of public-health services could pre-
vent the high number of cases of pregnancies 
in which the mother is unaware of conception, 
thus allowing commencement of supplementa-
tion prior to pregnancy and throughout mater-
nity. This measure would not only prevent folic 
acid deficiency during the most critical period 
of embryogenesis but also avoid indiscriminate 
use of the supplement. Evidence has shown that, 
even in developed countries such as Japan, infor-
mation on the role of periconceptional intake of 
folic acid is not sufficiently disseminated among 
young women 101. Improvements in maternal 
health and the provision of quality health servic-
es in the area of human reproduction constitute 
essential actions to eliminate the multiple causes 
underlying infant mortality.
From a nutritional standpoint, since folate is 
mainly found in fresh fruit and leafy vegetables, 
individuals who are deficient in the vitamin due 
to under-consumption of these foods can also 
present deficiency in other important nutrients. 
Thus, the incentive to consume fruit, legumes 
and vegetables, besides having no adverse ef-
fects, can yield greater health benefits. All health 
professionals involved in the contraceptive care 
of women can contribute by propagating this in-
formation, placing emphasis on the protective 
effects of a healthy diet, particularly of a folate-
rich diet.
Scientific evidence indicates that the strategy 
with the greatest impact in reducing the preva-
lence of maternal anemia and neural tube de-
fects is supplementation aimed at target groups 
with close monitoring of treatment doses and 
duration. It is important to bear in mind that 
the benefits of fortification are clear, but that 
various adverse effects exist, and for every preg-
nancy with neural tube defect prevented, hun-
dreds of people may be exposed to high levels 
of folic acid intake. A cautious approach to im-
plementing universal fortification policies has 
been urged since 1995 102. Many countries have 
opted against mandatory fortification, primarily 
because additional health benefits are not yet 
proven in clinical trials, secondly due to the un-
known risks, and thirdly out of respect for indi-
viduals’ freedom of choice 103.
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Table 4
Studies assessing adverse effects of excessive synthetic folic acid intake.
Reference Place/Year Study design Characteristics 
of population 
(n/age/
physiological 
status)
Exposure (dose/
duration/period)
Results/Adverse effects
Troen et al. 89 USA/2006 Transversal 
(subsample of 
population of 
a study in the 
greater Seattle 
recruited for 
an intervention 
trial)
Healthy 
premenopausal 
women 
(n = 105)
Dietary intake 
(measured by 
food frequency 
questionnaire) 
and number of 
supplement pills/
day, in the year 
preceding blood 
collection
Women with high folate intake (> 233µg/day) had lower 
cytotoxicity of natural killer (NK) cells if they also took folic 
acid supplements (> 400µg) (p = 0.02). NK cells are part 
of the specific immune response and can destroy a variety 
of cells infected by virus and tumor cells, protecting 
against cancer 
Kelly et al. 90 Ireland/1997 Uncontrolled, 
randomized, 
clinical trial
Healthy 
volunteers (5 
men and 18 
women), aged 
18-42 years
Intake of bread 
fortified with 
266µg folic acid/
meal, for 5 days 
Presence of unmetabolized folic acid in plasma
Stolzenberg-
Solomon et al. 95
USA/2006 Cohort 25,400 
women (aged 
55-74 years) 
from Prostate, 
Lung, 
Colorectal 
and Ovarian 
Cancer 
Screening 
Trial
Dietary intake 
(measured by 
food frequency 
questionnaire) 
and multivitamin 
in the year 
preceding blood 
collection
Adjusted RR were 1.19 (95%CI: 1.01; 1.41; p for trend 
= 0.04) for women reporting use of 400µg/day of folic 
acid supplements compared with those reporting no 
supplement use. Comparison between greatest and 
lowest quintile yielded an adjusted RR of 1.04 (95%CI: 
0.83; 1.31; p for trend = 0.56) and 1.32 (95%CI: 1.04; 
1.68; p for trend = 0.03) for intake of dietary folate and 
total folate, respectively
Cole et al. 96 USA/2007 Controlled, 
double-blind, 
randomized, 
clinical trial
1,021 men 
and women 
(21-80 years) 
with recent 
history of 
colorectal 
adenomas 
and no 
previous 
intestinal 
carcinoma
Intervention 
group: 1mg/day 
of folic acid 
(n = 516), control 
group: placebo 
(n = 505)
Both groups 
were randomized 
separately to 
receive aspirin 
(81 or 325mg/
day) or placebo
During the first 3 years, the incidence of at least 1 
colorectal adenoma was 44.1% for the folic acid group 
(n = 221) and 42.4% for the placebo group (n = 206) 
(RR = 1.04; 95%CI: 0.90; 1.20; p = 0.58). The incidence 
of at least one advanced lesion was 11.4% for the folic 
acid group (n = 57) and 8.6% for the placebo group 
(n = 42) (RR = 1.32; 95%CI: 0. 90; 1.92; p = 0.15). In 
subsequent 5-year follow-up, the incidence of at least 
one colorectal adenoma was 41.9% for the folic acid 
group (n = 127) and 37.2% for the placebo group (n = 
113) (RR = 1.13; 95%CI: 0.93; 1.37; p = 0.23); and the 
incidence of at least one advanced lesion was 11.6% for 
the folic acid group (n = 35) and 6.9% for the placebo 
group (n = 21) (RR = 1.67; 95%CI: 1.00; 2.80; p = 0.05). 
Folic acid was associated with higher risks of having 3 
or more adenomas and non-colorectal cancers. After 
a 10-year follow-up, a 52% higher risk of recurrence of 
high-grade dysplastic adenomas was observed in those 
taking folic acid supplements (10.9%), compared to 
those taking placebo (4.3%) (RR = 2.52; 95%CI: 1.28; 
4.98; p = 0.008)
(continues)
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Table 4 (continued)
Reference Place/Year Study design Characteristics 
of population 
(n/age/
physiological 
status)
Exposure (dose/
duration/period)
Results/Adverse effects
Basten et al. 98 England/2006 Controlled, 
double-blind, 
randomized, 
clinical trial
Healthy male 
and female 
volunteers 
(n = 56), aged 
20-60 years
Intervention 
group: 1.2mg 
folic acid, control 
group: glucose
A significant decrease in incorporation of uracil 
(p < 0.05) was observed in the supplemented group 
compared with the placebo group. Incorporation of 
uracil is more sensitive to folic acid status in healthy 
individuals than other biomarkers of DNA damage
Morris et al. 100 USA/2007 Transversal 
population-
based
1,459 elderly 
(≥ 60 years) 
participants in 
the National 
Health and 
Nutrition 
Examination 
Survey 
(NHANES)
Vitamin B12 
status and sera 
methylmalonic 
acid levels (MMA)
Low vitamin 
B12 status was 
defined as sera 
vitamin B12 
concentrations  
< 148ρmol/L 
or sera MMA 
concentrations > 
210nmol/L
In the group with low vitamin B12 status, sera folate 
> 59nmol/L (80th  percentile), in contrast to sera folate 
= 59 nmol/L, was associated with  anemia (OR = 3.1; 
95%CI 1.5; 6.6) and cognitive damage (OR = 2.6; 
95%CI: 1.1; 6.1). In the group with normal B12 vitamin 
status, the OR for high versus normal sera folate for 
these outcomes were < 1.0 (pinteraction < 0.05), but 
significantly < 1.0 only for cognitive damage (0.4; 
95%CI: 0.2; 0.9)
OR: odds ratio; RR: relative risk.
Resumo
A deficiência de ácido fólico tem sido associada ao ris-
co de anemia e outros desfechos adversos na gravidez, 
como os defeitos no tubo neural. As recomendações 
atuais para prevenção de tais agravos são considera-
das difíceis de se alcançar apenas por meio da dieta, 
e a suplementação com ácido fólico e a adição dessa 
vitamina a alimentos sob a forma de fortificação re-
presentam esforços centrais no controle da sua defici-
ência. É necessário, porém, conhecer as características 
da dieta habitual e o uso de suplementos entre mulhe-
res em idade reprodutiva, com avaliação adequada de 
outros nutrientes da dieta. Ao lado dos efeitos benéficos 
observados em ensaios clínicos aleatórios controlados, 
riscos à saúde da população têm sido avaliados e lar-
gamente discutidos no meio científico: para que uma 
fração seja beneficiada pela fortificação, centenas de 
pessoas são expostas a quantidades de ácido fólico tal-
vez elevadas e provavelmente incomuns, em quantida-
de e apresentação química, ao organismo humano.
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